Rationale, study design and implementation of the COLM study: The combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients

Toshio Ogihara, Takao Saruta, Hiromi Rakugi, Kazuaki Shimamoto, Sadayoshi Ito, Hiroaki Matsuoka, Masatsugu Horiuchi, Tsutomu Imaizumi, Shuichi Takishita, Jitsuo Higaki, Shigehiro Katayama, Ikuo Saito, Kazuyuki Shimada

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The COLM study is an investigator-initiated trial comparing the combination therapy using an angiotensin II receptor blocker (ARB), olmesartan, and a calcium channel blocker (CCB) with that using an ARB and a diuretic in high-risk elderly hypertensive patients. Here we describe the rationale and study design. Olmesartan was administered concomitantly with a long-acting dihydropyridine CCB (ARB/CCB group) or with a low-dose diuretic (ARB/diuretic group) to elderly hypertensive patients with a history of or risk factors for cardiovascular disease. Cardiovascular morbidity and mortality as a primary end point were compared between the two groups, with the target blood pressure (BP) being <140mmHg for systolic BP and <90mmHg for diastolic BP. Safety and tolerability will also be investigated. A total of more than 4000 patients were recruited and will be followed up for at least 3 years.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalHypertension Research
Volume32
Issue number2
DOIs
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Rationale, study design and implementation of the COLM study: The combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients'. Together they form a unique fingerprint.

Cite this